Cancer and the Immune System: The History and Background of Immunotherapy

被引:349
作者
Abbott, Maura [1 ,2 ]
Ustoyev, Yelena [2 ]
机构
[1] Columbia Univ, Sch Nursing, 560 West 168th St,Room 532, New York, NY 10032 USA
[2] Columbia Univ, Irving Med Ctr, New York, NY USA
关键词
History; Immunotherapy history; Innate immunity; Adaptive immunity; Cancer immunotherapy; CELL LYMPHOMA; T-CELLS; IMMUNOSURVEILLANCE; PRINCIPLES; THERAPY; SARCOMA;
D O I
10.1016/j.soncn.2019.08.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: This article will outline the link between the immune system and cancer, and provide a historical timeline of immunotherapy developmental milestones. Data Sources: Published data and peer reviewed publications/manuscripts, and textbook chapters. Conclusion: Science has provided a greater understanding of the interactions between cancer and the human immune system. As this knowledge has grown, there has been significant progress in the development of clinically effective cancer immunotherapies. Implications for Nursing Practice: Nurses' knowledge of the different types of immunity and the interaction of cancer cells with the immune system provides foundational knowledge for understanding cancer immunotherapy. Familiarity with the history of cancer immunotherapy will allow nurses to better comprehend why immunotherapy is now a pillar of cancer treatment that continues to develop. This knowledge will translate to better understanding and provision of care for patients receiving immunotherapy for the treatment of cancer. (C) 2019 Elsevier Inc. All rights reserved.
引用
收藏
页数:5
相关论文
共 35 条
[1]  
[Anonymous], 2009, Am J Immunol
[2]   Tumour necrosis factor and cancer [J].
Balkwill, Frances .
NATURE REVIEWS CANCER, 2009, 9 (05) :361-371
[3]   Cancer and the immune system: an overview - Introduction [J].
Blair, G. E. ;
Cook, G. P. .
ONCOGENE, 2008, 27 (45) :5868-5868
[4]   Oncology Meets Immunology: The Cancer-Immunity Cycle [J].
Chen, Daniel S. ;
Mellman, Ira .
IMMUNITY, 2013, 39 (01) :1-10
[5]   The treatment of sarcoma with the mixed toxins of erysipelas and bacillus prodigiosus [J].
Coley, WB .
BOSTON MEDICAL AND SURGICAL JOURNAL, 1908, 158 :175-182
[6]  
Coley WB, 1893, AM J MED SCI, V105
[7]   Cancer Immunotherapy [J].
Couzin-Frankel, Jennifer .
SCIENCE, 2013, 342 (6165) :1432-1433
[8]   Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited [J].
Decker, William K. ;
Safdar, Amar .
CYTOKINE & GROWTH FACTOR REVIEWS, 2009, 20 (04) :271-281
[9]   Interferon-γ and cancer immunoediting [J].
Dunn, GP ;
Ikeda, H ;
T Bruce, A ;
Koebel, C ;
Uppaluri, R ;
Bui, J ;
Chan, R ;
Diamond, M ;
White, JM ;
Sheehan, KCF ;
Schreiber, RD .
IMMUNOLOGIC RESEARCH, 2005, 32 (1-3) :231-245
[10]   A critical function for type I interferons in cancer immunoediting [J].
Dunn, GP ;
Bruce, AT ;
Sheehan, KCF ;
Shankaran, V ;
Uppaluri, R ;
Bui, JD ;
Diamond, MS ;
Koebel, CM ;
Arthur, C ;
White, JM ;
Schreiber, RD .
NATURE IMMUNOLOGY, 2005, 6 (07) :722-729